Home Logon FTA Investment Managers Blog Subscribe About Us Contact Us

Search by Ticker, Keyword or CUSIP       
Blog Home
Bob Carey
Chief Market Strategist
X •  LinkedIn

  Biotech Pipelines and “Pharmerging Markets” offer Growth Potential
Posted Under: Sectors
Supporting Image for Blog Post


View from the Observation Deck

  1. Global pharmaceutical sales by PhRMA member companies totaled an estimated $295.5 billion in 2011 (see chart), with 38% occurring outside the U.S. In 2006, that figure was 30%.
  2. These nations followed the U.S.'s 62% share of global sales (by PhRMA members): Japan (4.6%); France (3.3%); Germany (2.7%); Italy (2.3%); and Canada (2.3%).
  3. So-called "Big Pharma" is looking to expand heavily into emerging markets ("pharmerging"), particularly in Brazil, Russia, India & China (BRICs), where governments are investing more in health care. (IMAP, Inc.)
  4. In 2010, the BRIC countries accounted for about 3.5% of total global sales. (PhRMA)
  5. Approximately $89.5 billion worth of branded pharmaceuticals are scheduled to lose patent protection between 2009 and 2014. Generic sales are expected to grow from $107.8 billion in 2009 to $129.3 billion in 2014. (IMAP, Inc.)
  6. Biologic sales, on the other hand, are expected to grow by $41 billion between 2009 and 2014. (IMAP, Inc.)
  7. The fastest way for a drug company to acquire new medicines is through mergers and acquisitions and through licensing agreements, in our opinion.
  8. In 2012, some drug companies have been willing to pay premiums 71%, on average, above a biotechnology company's average 20-day stock price (deals > $500 million in 2012) to acquire them. (Bloomberg)
Posted on Tuesday, May 1, 2012 @ 4:32 PM • Post Link Print this post Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Search Posts
Market Commentary and Analysis
Market Commentary Video
Monthly Talking Points
Quarterly Newsletter
Market Observations
Subscribe To Receive Email

The Markets Fight Through the Headlines
China May Only Pose a Near-Term Challenge for Price of Copper
Agriculture Prices Take Breather Following Strong Decade
It’s Tough To Stay On Top!
Job Creation to Drive REIT Recovery from this Point Forward
The Question of Recession
Sell in May and Go Away! Think about it first.
Will the 2016 Summer Olympics Boost the Bovespa?
India's Stock Market Rebounding Despite Stubborn Inflation
Technology Stocks Have More to Give
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
Follow First Trust:  
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2024 All rights reserved.